David Michael Johnson - 20 Jun 2024 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Director
Signature
/s/ Julie Feder, Attorney-in-fact
Issuer symbol
AURA
Transactions as of
20 Jun 2024
Net transactions value
$0
Form type
4
Filing time
24 Jun 2024, 16:05:23 UTC
Previous filing
13 Nov 2023
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +10,500 +7.7% $0.000000 146,167 20 Jun 2024 Direct F1
holding AURA Common Stock 75,000 20 Jun 2024 By NEJ09 IRREVOCABLE TRUST F2
holding AURA Common Stock 75,000 20 Jun 2024 By NEJ12 IRREVOCABLE TRUST F3
holding AURA Common Stock 139,672 20 Jun 2024 By Velocity Capital Management F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +14,500 $0.000000 14,500 20 Jun 2024 Common Stock 14,500 $6.93 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
F2 The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
F3 The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
F4 Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of.
F5 This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.